Neeraj Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neeraj Kumar has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Gunja Mishra
Indian Council of Medical Research (ICMR)‐National Institute of Pathology Safdarjung Hospital Campus New Delhi India
3 shared publicationsNarinder K. Mehra
Emeritus Scientist (ICMR), and Former Dean (Research) All India Institute of Medical Sciences New Delhi India
3 shared publicationsGurvinder Kaur
Laboratory Oncology Unit, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
2 shared publicationsHarpreet Singh
Biomedical Informatics Division, Indian Council of Medical Research, New Delhi, India
2 shared publications- Neihenuo Chuzho
Indian Council of Medical Research (ICMR)‐National Institute of Pathology Safdarjung Hospital Campus New Delhi India
2 shared publications - Nikhil Tandon
Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi India
2 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7216
Immunotherapy for Cancer: Current Advances and Future Directions
Immunotherapy delivers a fundamental shift in the treatment of multiple cancers, offering hope for patients with cancer. Unlike conventional therapies, it leverages the patient’s immune system to precisely identify and destroy cancer cells. The remarkable journey of immunotherapy’s has revolutionized oncology and paved the way for the development of modern immunotherapies. Several approaches are applied for immunotherapy, including immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, tumor microenvironment reprogramming, monoclonal antibodies, cytokine therapies, oncolytic virus therapy and combination strategies. Various immunotherapies are being used for different types of cancers like skin, lung, bladder, kidney, liver, breast and blood cancers. Despite providing an effective cancer treatment, immunotherapies face some challenges in their clinical implementation. To overcome these limitations, future directions emphasize the development of personalized and combination therapies, the incorporation of AI and a good delivery system. The main aim of this review is to give an overview of the journey of evolution, different approaches, limitations, advances and future development for immunotherapy in cancer treatment.
- 13 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7216
Open AccessImmunotherapy for Cancer: Current Advances and Future Directions
Immunotherapy delivers a fundamental shift in the treatment of multiple cancers, offering hope for patients with cancer. Unlike conventional therapies, it leverages the patient’s immune system to precisely identify and destroy cancer cells. The remarkable journey of immunotherapy’s has revolutionized oncology and paved the way for the development of modern immunotherapies. Several approaches are applied for immunotherapy, including immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, tumor microenvironment reprogramming, monoclonal antibodies, cytokine therapies, oncolytic virus therapy and combination strategies. Various immunotherapies are being used for different types of cancers like skin, lung, bladder, kidney, liver, breast and blood cancers. Despite providing an effective cancer treatment, immunotherapies face some challenges in their clinical implementation. To overcome these limitations, future directions emphasize the development of personalized and combination therapies, the incorporation of AI and a good delivery system. The main aim of this review is to give an overview of the journey of evolution, different approaches, limitations, advances and future development for immunotherapy in cancer treatment.
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
The exact cause of psoriasis is still unclear and there is no treatment available for its permanent reemission. The available biologics for disease treatment, are stated to be associated with a high cost of treatment, a significantly increased risk of serious infections, and have also been reported to show major contradictions in patients with tuberculosis and cardiovascular disorders. Therefore, drug repurposing could be an appealing strategy to find novel treatments for psoriasis, saving time, cost and with viable chance of success. The goal of the present study was to identify the FDA approved drugs which can be proposed as potential anti-psoriasis drugs. The known drug target interactions of 19 autoimmune diseases, 4 cardiovascular risk factors, and each of infectious, lung, and mood disorders were retrieved using various public databases, i.e., DrugBank, PharmGKB, clinicaltrial.gov database, TTD, CTD, and the Unified Medical Language System NDF-RT. The drug target interaction of prioritised drugs, obtained using molecular function GO mappings from the QuickGO database through NBI score was analysed using a molecular docking approach. Further, one-SVM algorithm prediction was done to validate the docking outcome and molecular dynamics simulation of top drug-target molecule was performed to propose potential anti-psoriasis drugs. The study identified Pioglitazone, Trimipramine and Dimetindene as top three contender amongst many other drugs as a new indication against psoriasis.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
Open AccessRepurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
The exact cause of psoriasis is still unclear and there is no treatment available for its permanent reemission. The available biologics for disease treatment, are stated to be associated with a high cost of treatment, a significantly increased risk of serious infections, and have also been reported to show major contradictions in patients with tuberculosis and cardiovascular disorders. Therefore, drug repurposing could be an appealing strategy to find novel treatments for psoriasis, saving time, cost and with viable chance of success. The goal of the present study was to identify the FDA approved drugs which can be proposed as potential anti-psoriasis drugs. The known drug target interactions of 19 autoimmune diseases, 4 cardiovascular risk factors, and each of infectious, lung, and mood disorders were retrieved using various public databases, i.e., DrugBank, PharmGKB, clinicaltrial.gov database, TTD, CTD, and the Unified Medical Language System NDF-RT. The drug target interaction of prioritised drugs, obtained using molecular function GO mappings from the QuickGO database through NBI score was analysed using a molecular docking approach. Further, one-SVM algorithm prediction was done to validate the docking outcome and molecular dynamics simulation of top drug-target molecule was performed to propose potential anti-psoriasis drugs. The study identified Pioglitazone, Trimipramine and Dimetindene as top three contender amongst many other drugs as a new indication against psoriasis.
- 28 October 2024
- Published by Taylor & Francis
- p. 60-77
Chemical-Induced Alzheimer's Disease Models with an Emphasis on Therapeutic Significance and Limitation of Natural Products
Alzheimer's disease (AD) is a neurodegenerative disorder identified by alterations in brain cells that lead to deposits of certain proteins, and it is one of the leading causes of dementia. Several agents, such as chemicals, drugs etc., have been used to develop AD-like symptoms in rodents in order to understand the mechanisms of the disease and therapeutic action of drugs for a range of cognitive abnormalities. Meanwhile, the already-marketed compounds or drugs are mostly synthetic and therapeutic action always a matter of concern mainly because of their complex nature and off-target issues. The known targets include prevention of amyloid senile plaques, acetylcholinesterase, inflammatory pathways, oxidation products, specific brain receptors, etc. In order to explore new alternatives for AD treatment, products of natural origin have gained attention in the pharmaceutical industry because of their neuroprotective attributes by targeting several pathological mechanisms. This chapter describe chemical-induced neurological problems and possible drug targets for AD management. Moreover, medicinal plants and their active compounds that are used for the management and treatment of AD are also discussed.
- 28 October 2024
- Published by Taylor & Francis
- p. 60-77
Chemical-Induced Alzheimer's Disease Models with an Emphasis on Therapeutic Significance and Limitation of Natural Products
Alzheimer's disease (AD) is a neurodegenerative disorder identified by alterations in brain cells that lead to deposits of certain proteins, and it is one of the leading causes of dementia. Several agents, such as chemicals, drugs etc., have been used to develop AD-like symptoms in rodents in order to understand the mechanisms of the disease and therapeutic action of drugs for a range of cognitive abnormalities. Meanwhile, the already-marketed compounds or drugs are mostly synthetic and therapeutic action always a matter of concern mainly because of their complex nature and off-target issues. The known targets include prevention of amyloid senile plaques, acetylcholinesterase, inflammatory pathways, oxidation products, specific brain receptors, etc. In order to explore new alternatives for AD treatment, products of natural origin have gained attention in the pharmaceutical industry because of their neuroprotective attributes by targeting several pathological mechanisms. This chapter describe chemical-induced neurological problems and possible drug targets for AD management. Moreover, medicinal plants and their active compounds that are used for the management and treatment of AD are also discussed.
- Open Access
- 13 June 2023
- Published by Wiley in Journal of Diabetes
- Vol. 15 (7) , 607-621
HLA‐DR3 mediated CD4 T cell response against GAD65 in type 1 diabetes patients
Aim: We planned this study to identify diabetogenic glutamic acid decarboxylase (GAD65) peptides possibly responsible for human leucocyte antigen (HLA)‐DR3/DQ2‐mediated activation of GAD65‐specific CD4 T cells in type 1 diabetes (T1D).Methods: Top 30 GAD65 peptides, found to strongly bind in silico with HLA‐DR3/DQ2 molecules, were selected and grouped into four pools. The peptides were used to stimulate CD4 T cells of study subjects in 16‐h peripheral blood mononuclear cell culture. CD4 T cells' stimulation in terms of interferon‐gamma (IFN‐γ), interleukin (IL)‐17, tumor necrosis factor‐alpha (TNF‐α), and IL‐10 expression was analyzed using flow cytometry.Results: Although all four GAD65 peptide pools (PP1‐4) resulted in significantly higher expression of IFN‐γ by CD4 T cells (p = .003, p < .0001, p = .026, and p = .002, respectively), only pool 2 showed significant increase in IL‐17 expression (p < .0001) in T1D patients vs healthy controls. Interpeptide group comparison for immunogenicity revealed significantly higher IFN‐γ and IL‐17 expressions and significantly lower IL‐10 expression for PP2 compared to other groups (p < .0001, p = .02, and p = .04, respectively) in patients but not in controls. Further, group 2 peptides resulted in significant increase in CD4 T cells' expression of IFN‐γ and IL‐17 (p = .002 for both) and significant decrease in IL‐10 (p = .04) in HLA‐DRB1*03‐DQA1*05‐DQB1*02+ patients vs HLA‐DRB1*03‐DQA1*05‐DQB1*02+ controls. The CD4 T cells' expression of IL‐17 was significantly higher (p = .03) in recently diagnosed vs long‐standing HLA‐DRB1*03‐DQA1*05‐DQB1*02+ T1D patients.Conclusion: GAD65 peptides, particularly those belonging to PP2, induced CD4 T cells to express IFN‐γ and IL‐17 cytokines in T1D patients, suggesting that group 2 peptides possibly presented by HLA‐DR3 molecule to CD4 T cells shift immune balance toward inflammatory phenotype in patients.
- 13 June 2023
- Published by Wiley in Journal of Diabetes
- Vol. 15 (7) , 607-621
Open AccessHLA‐DR3 mediated CD4 T cell response against GAD65 in type 1 diabetes patients
Aim: We planned this study to identify diabetogenic glutamic acid decarboxylase (GAD65) peptides possibly responsible for human leucocyte antigen (HLA)‐DR3/DQ2‐mediated activation of GAD65‐specific CD4 T cells in type 1 diabetes (T1D).Methods: Top 30 GAD65 peptides, found to strongly bind in silico with HLA‐DR3/DQ2 molecules, were selected and grouped into four pools. The peptides were used to stimulate CD4 T cells of study subjects in 16‐h peripheral blood mononuclear cell culture. CD4 T cells' stimulation in terms of interferon‐gamma (IFN‐γ), interleukin (IL)‐17, tumor necrosis factor‐alpha (TNF‐α), and IL‐10 expression was analyzed using flow cytometry.Results: Although all four GAD65 peptide pools (PP1‐4) resulted in significantly higher expression of IFN‐γ by CD4 T cells (p = .003, p < .0001, p = .026, and p = .002, respectively), only pool 2 showed significant increase in IL‐17 expression (p < .0001) in T1D patients vs healthy controls. Interpeptide group comparison for immunogenicity revealed significantly higher IFN‐γ and IL‐17 expressions and significantly lower IL‐10 expression for PP2 compared to other groups (p < .0001, p = .02, and p = .04, respectively) in patients but not in controls. Further, group 2 peptides resulted in significant increase in CD4 T cells' expression of IFN‐γ and IL‐17 (p = .002 for both) and significant decrease in IL‐10 (p = .04) in HLA‐DRB1*03‐DQA1*05‐DQB1*02+ patients vs HLA‐DRB1*03‐DQA1*05‐DQB1*02+ controls. The CD4 T cells' expression of IL‐17 was significantly higher (p = .03) in recently diagnosed vs long‐standing HLA‐DRB1*03‐DQA1*05‐DQB1*02+ T1D patients.Conclusion: GAD65 peptides, particularly those belonging to PP2, induced CD4 T cells to express IFN‐γ and IL‐17 cytokines in T1D patients, suggesting that group 2 peptides possibly presented by HLA‐DR3 molecule to CD4 T cells shift immune balance toward inflammatory phenotype in patients.
- 13 April 2023
- Published by Springer Nature in 3 Biotech
- Vol. 13 (5) , 1-11
Exploring the molecular underpinning of psoriasis and its associated comorbidities through network approach: cross talks of genes and pathways
Patients with psoriasis often complain of several linked disorders including autoimmune and cardiometabolic diseases. Understanding of molecular link between psoriasis and associated comorbidities would be of great interest at the point of patient care management. Integrative unbiased network approach, indicates significant unidirectional gene overlap between psoriasis and its associated comorbid condition including obesity (31 upregulated and 26 downregulated), ischemic stroke (14 upregulated and 2 downregulated), dyslipidaemia (5 upregulated, 5 downregulated), atherosclerosis (8 upregulated and 1 downregulated) and type II diabetes (5 upregulated, 5 downregulated). The analysis revealed substantial gene sharing among the different psoriasis-associated comorbidities. Molecular comorbidity index determining the strength of the interrelation between psoriasis and its comorbidities indicates prevalence of dyslipidaemia followed by type II diabetes among psoriasis patients. The Jaccard coefficient indices revealed psoriasis shared maximum number of biological pathways with dyslipidaemia followed by type 2 diabetes, ischemic stroke, obesity and atherosclerosis. Moreover, pathway annotation highlighted nearly 45 shared pathways amongst psoriasis and its comorbidities and a substantial number of shared pathways was found among multi-morbidities. Overall, the present study established conceivable link between psoriasis and comorbid diseases. The shared genes and overlapped pathways may be explored as a common productive target for psoriasis and its comorbid conditions.
- 13 April 2023
- Published by Springer Nature in 3 Biotech
- Vol. 13 (5) , 1-11
Exploring the molecular underpinning of psoriasis and its associated comorbidities through network approach: cross talks of genes and pathways
Patients with psoriasis often complain of several linked disorders including autoimmune and cardiometabolic diseases. Understanding of molecular link between psoriasis and associated comorbidities would be of great interest at the point of patient care management. Integrative unbiased network approach, indicates significant unidirectional gene overlap between psoriasis and its associated comorbid condition including obesity (31 upregulated and 26 downregulated), ischemic stroke (14 upregulated and 2 downregulated), dyslipidaemia (5 upregulated, 5 downregulated), atherosclerosis (8 upregulated and 1 downregulated) and type II diabetes (5 upregulated, 5 downregulated). The analysis revealed substantial gene sharing among the different psoriasis-associated comorbidities. Molecular comorbidity index determining the strength of the interrelation between psoriasis and its comorbidities indicates prevalence of dyslipidaemia followed by type II diabetes among psoriasis patients. The Jaccard coefficient indices revealed psoriasis shared maximum number of biological pathways with dyslipidaemia followed by type 2 diabetes, ischemic stroke, obesity and atherosclerosis. Moreover, pathway annotation highlighted nearly 45 shared pathways amongst psoriasis and its comorbidities and a substantial number of shared pathways was found among multi-morbidities. Overall, the present study established conceivable link between psoriasis and comorbid diseases. The shared genes and overlapped pathways may be explored as a common productive target for psoriasis and its comorbid conditions.
- Open Access
- 27 December 2021
- Published by Wiley in Journal of Diabetes Research
- Vol. 2021, 1-13
Differential HLA Association of GAD65 and IA2 Autoantibodies in North Indian Type 1 Diabetes Patients
The human leucocyte antigen (HLA) association with type 1 diabetes (T1D) is well known but there are limited studies investigating the association between β-cell autoantibodies and HLA genes. We evaluated the prevalence of GAD65 and IA-2 autoantibodies (GADA and IA2A) in 252 T1D patients from North India and investigated the genetic association of GADA and IA2A with HLA class I and class II genes/haplotypes. GADA and IA2A were detected in 50.79% and 15.87% of T1D patients, respectively, while only 8.73% had both GADA and IA2A. HLA-DRB103 was observed to be significantly higher in GADA+ T1D patients as compared to GADA– (91.41% vs. 66.13%, Bonferroni- ; ; 95% CI: 2.67-11.08). Similarly, HLA-DQB102 was found to be significantly increased in GADA+ patients (94.53%, ; ; 95% CI: 2.7-14.49) as compared to GADA– (73.39%). The frequencies of HLA-DRB104 and DQB103 were increased in IA2A+ patients (45.0% and 52.5%, respectively) as compared to that in IA2A– (25.94% and 33.96%, respectively). Further, the frequency of DRB103-DQB102 haplotype was found to be significantly increased in GADA+ T1D patients as compared to GADA- (60.55% vs. 41.94%, ; ;
- 27 December 2021
- Published by Wiley in Journal of Diabetes Research
- Vol. 2021, 1-13
Open AccessDifferential HLA Association of GAD65 and IA2 Autoantibodies in North Indian Type 1 Diabetes Patients
The human leucocyte antigen (HLA) association with type 1 diabetes (T1D) is well known but there are limited studies investigating the association between β-cell autoantibodies and HLA genes. We evaluated the prevalence of GAD65 and IA-2 autoantibodies (GADA and IA2A) in 252 T1D patients from North India and investigated the genetic association of GADA and IA2A with HLA class I and class II genes/haplotypes. GADA and IA2A were detected in 50.79% and 15.87% of T1D patients, respectively, while only 8.73% had both GADA and IA2A. HLA-DRB103 was observed to be significantly higher in GADA+ T1D patients as compared to GADA– (91.41% vs. 66.13%, Bonferroni- ; ; 95% CI: 2.67-11.08). Similarly, HLA-DQB102 was found to be significantly increased in GADA+ patients (94.53%, ; ; 95% CI: 2.7-14.49) as compared to GADA– (73.39%). The frequencies of HLA-DRB104 and DQB103 were increased in IA2A+ patients (45.0% and 52.5%, respectively) as compared to that in IA2A– (25.94% and 33.96%, respectively). Further, the frequency of DRB103-DQB102 haplotype was found to be significantly increased in GADA+ T1D patients as compared to GADA- (60.55% vs. 41.94%, ; ;
- 7 January 2019
- Published by Wiley in Journal of Diabetes
- Vol. 11 (9) , 719-728
Diverse human leukocyte antigen association of type 1 diabetes in north India
Background: Type 1 diabetes (T1D) is a complex disease, with involvement of various susceptibility genes. Human leukocyte antigen (HLA) on chromosome 6p21 is major susceptibility region. This study examined genetic association of HLA genes with T1D.Methods: The study recruited 259 T1D patients and 706 controls from north India. PCR‐SSP and LiPA were used to type HLA Class I and II alleles.Results: At HLA Class I locus, HLA‐A*02, A*26, B*08 and B*50 were significantly increased in patients vs controls (39.8% vs 28.9% [Bonferroni‐corrected P {Pc} = 0.032], 24.7% vs 9.6% [Pc = 4.83 × 10−8], 37.2% vs 15.7% [Pc = 1.92 × 10−9], and 19.4% vs 5.5% [Pc = 4.62 × 10−9], respectively). Similarly, in Class II region, DRB1*03 showed a strong positive association with T1D (78.7% vs 17.5% in controls; P = 1.02 × 10−9). Association of DRB1*04 with T1D (28.3% vs 15.5% in controls; Pc = 3.86 × 10−4) was not independent of DRB1*03. Negative associations were found between T1D and DRB1*07, *11, *13, and *15 (13.8% vs 26.1% in controls [Pc = 0.00175], 3.9% vs 16.9% in controls [Pc = 6.55× 10−6], 5.5% vs 21.6% in controls [Pc = 2.51 × 10−7], and 16.9% vs 43.9% in controls [Pc = 9.94× 10−10], respectively). Compared with controls, patients had significantly higher haplotype frequencies of A*26‐B*08‐DRB1*03‐DQA1*05‐DQB1*02 (10.43% vs 1.96%; P = 7.62 × 10−11), A*02‐B*50‐DRB1*03‐DQA1*05‐DQB1*02 (6.1% vs 0.71%; P = 2.19 × 10−10), A*24‐B*08‐DRB1*03‐DQA1*05‐DQB1*02 (4.72% vs 0.8%; P = 5.4 × 10−7), A*02‐B*08‐DRB1*03‐DQA1*05‐DQB1*02 (2.36% vs 0.18%; P = 3.6 × 10−5), and A*33‐B*58‐DRB1*03‐DQA1*05‐DQB1*02 (4.33% vs 1.25%; P = 0.00019).Conclusions: In north India, T1D is independently associated only with HLA‐DRB1*03 haplotypes, and is negatively associated with DRB1*07, *11, *13, and *15.
- 7 January 2019
- Published by Wiley in Journal of Diabetes
- Vol. 11 (9) , 719-728
Diverse human leukocyte antigen association of type 1 diabetes in north India
Background: Type 1 diabetes (T1D) is a complex disease, with involvement of various susceptibility genes. Human leukocyte antigen (HLA) on chromosome 6p21 is major susceptibility region. This study examined genetic association of HLA genes with T1D.Methods: The study recruited 259 T1D patients and 706 controls from north India. PCR‐SSP and LiPA were used to type HLA Class I and II alleles.Results: At HLA Class I locus, HLA‐A*02, A*26, B*08 and B*50 were significantly increased in patients vs controls (39.8% vs 28.9% [Bonferroni‐corrected P {Pc} = 0.032], 24.7% vs 9.6% [Pc = 4.83 × 10−8], 37.2% vs 15.7% [Pc = 1.92 × 10−9], and 19.4% vs 5.5% [Pc = 4.62 × 10−9], respectively). Similarly, in Class II region, DRB1*03 showed a strong positive association with T1D (78.7% vs 17.5% in controls; P = 1.02 × 10−9). Association of DRB1*04 with T1D (28.3% vs 15.5% in controls; Pc = 3.86 × 10−4) was not independent of DRB1*03. Negative associations were found between T1D and DRB1*07, *11, *13, and *15 (13.8% vs 26.1% in controls [Pc = 0.00175], 3.9% vs 16.9% in controls [Pc = 6.55× 10−6], 5.5% vs 21.6% in controls [Pc = 2.51 × 10−7], and 16.9% vs 43.9% in controls [Pc = 9.94× 10−10], respectively). Compared with controls, patients had significantly higher haplotype frequencies of A*26‐B*08‐DRB1*03‐DQA1*05‐DQB1*02 (10.43% vs 1.96%; P = 7.62 × 10−11), A*02‐B*50‐DRB1*03‐DQA1*05‐DQB1*02 (6.1% vs 0.71%; P = 2.19 × 10−10), A*24‐B*08‐DRB1*03‐DQA1*05‐DQB1*02 (4.72% vs 0.8%; P = 5.4 × 10−7), A*02‐B*08‐DRB1*03‐DQA1*05‐DQB1*02 (2.36% vs 0.18%; P = 3.6 × 10−5), and A*33‐B*58‐DRB1*03‐DQA1*05‐DQB1*02 (4.33% vs 1.25%; P = 0.00019).Conclusions: In north India, T1D is independently associated only with HLA‐DRB1*03 haplotypes, and is negatively associated with DRB1*07, *11, *13, and *15.
- 18 September 2015
- Published by Wiley in International Journal of Immunogenetics
- Vol. 42 (6) , 445-452
CTLA4+49G allele associates with early onset of type 1 diabetes in North Indians
Summary: Type 1 diabetes (T1D) is a complex autoimmune disease with strong genetic influence. In this study, we investigated +49A/G SNP (rs 231775) in exon 1 of cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) by PCR‐RFLP and its influence as a risk factor for the disease in the North Indian population. This polymorphism at codon 17 results in an amino acid substitution (Thr/Ala) in the leader peptide of the molecule. The study included 232 patients with T1D (age at onset of disease (AOD): 0.5–37 years) and 305 ethnically matched healthy controls. The DNA obtained from these 537 individuals was amplified using a set of specific primers followed by restriction enzyme digestion with Fnu4HI. The +49G allele as well as its homozygous genotype G/G was observed to be significantly higher in patients as compared to the healthy controls {(37.3% vs. 25.6%, P = 4.96E−05, OR = 1.73; 95%CI = 1.33–2.25) (15.52% vs. 6.6%, P = 0.001, OR = 2.62; 95% CI = 1.48–4.63) respectively}. The frequency of G/G genotype was significantly higher in patients with early age at onset of disease (AOD:P = 0.042, OR = 2.26; 95% CI = 1.09–4.67) as well as to that in the healthy controls (21.1% vs. 6.6%, P = 0.00004, OR = 3.8; 95% CI = 2.01–7.2). Further analysis revealed that the median AOD significantly reduced (P = 0.049) from 14 years in patients with A/A genotype to 11 and 10 years in those with A/G and G/G genotypes, respectively. These results suggest that CTLA4+49G allele, particularly in homozygous G/G condition, associates with early onset of T1D.
- 18 September 2015
- Published by Wiley in International Journal of Immunogenetics
- Vol. 42 (6) , 445-452
CTLA4+49G allele associates with early onset of type 1 diabetes in North Indians
Summary: Type 1 diabetes (T1D) is a complex autoimmune disease with strong genetic influence. In this study, we investigated +49A/G SNP (rs 231775) in exon 1 of cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) by PCR‐RFLP and its influence as a risk factor for the disease in the North Indian population. This polymorphism at codon 17 results in an amino acid substitution (Thr/Ala) in the leader peptide of the molecule. The study included 232 patients with T1D (age at onset of disease (AOD): 0.5–37 years) and 305 ethnically matched healthy controls. The DNA obtained from these 537 individuals was amplified using a set of specific primers followed by restriction enzyme digestion with Fnu4HI. The +49G allele as well as its homozygous genotype G/G was observed to be significantly higher in patients as compared to the healthy controls {(37.3% vs. 25.6%, P = 4.96E−05, OR = 1.73; 95%CI = 1.33–2.25) (15.52% vs. 6.6%, P = 0.001, OR = 2.62; 95% CI = 1.48–4.63) respectively}. The frequency of G/G genotype was significantly higher in patients with early age at onset of disease (AOD:P = 0.042, OR = 2.26; 95% CI = 1.09–4.67) as well as to that in the healthy controls (21.1% vs. 6.6%, P = 0.00004, OR = 3.8; 95% CI = 2.01–7.2). Further analysis revealed that the median AOD significantly reduced (P = 0.049) from 14 years in patients with A/A genotype to 11 and 10 years in those with A/G and G/G genotypes, respectively. These results suggest that CTLA4+49G allele, particularly in homozygous G/G condition, associates with early onset of T1D.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4
CTLA4 +49G allele in combination with HLA-DR3 associates with type 1 diabetes as well as its onset in North Indians
Type 1 diabetes is a complex autoimmune disease with a strong genetic influence. We have investigated the role of the CTLA4 (Cytotoxic T-lymphocyte associated antigen -4) exon 1 A49G polymorphism and its role as a risk factor for T1D in the North Indian population. We studied 232 type 1 diabetic patients and 200 healthy controls by PCR amplification followed by restriction enzyme digestion with FnU4HI. Allele G at +49 position in codon1 of CTLA 4 gene was significantly increased in type 1 diabetic patients as compared to that in healthy controls (37.3% in patients vs 29% in controls, p= 0.012, OR=1.46, 95%CI= 1.09-1.94 ). Further, the frequency of homozygous GG genotype was significantly increased among patients than controls (15.5% vs 5.0%, p=0.001, OR=3.49 (95% CI=1.7-7.13)). The patients with younger age at onset of disease (<14 years) had a significantly high frequency of G positive genotypes (A/G or G/G) than those with an older age at onset of disease (≥14 years) (66% vs 47.1%, p=0.007, OR=2.18 (95%CI=1.27-3.76). Further analysis involving the HLA data revealed that the CTLA4 +49G allele is not in linkage disequilibrium with the reported susceptible HLA-DR3 allele, however the susceptibility conferred by +49G allele as well as its effect on the disease onset was observed to be dependent on the presence of HLA-DR3 allele. These results suggest that CTLA4 +49G allele in the presence of HLA-DR3 allele not only confers susceptibility to T1D and but is a strong marker for acceleration of disease development
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4
Open AccessCTLA4 +49G allele in combination with HLA-DR3 associates with type 1 diabetes as well as its onset in North Indians
Type 1 diabetes is a complex autoimmune disease with a strong genetic influence. We have investigated the role of the CTLA4 (Cytotoxic T-lymphocyte associated antigen -4) exon 1 A49G polymorphism and its role as a risk factor for T1D in the North Indian population. We studied 232 type 1 diabetic patients and 200 healthy controls by PCR amplification followed by restriction enzyme digestion with FnU4HI. Allele G at +49 position in codon1 of CTLA 4 gene was significantly increased in type 1 diabetic patients as compared to that in healthy controls (37.3% in patients vs 29% in controls, p= 0.012, OR=1.46, 95%CI= 1.09-1.94 ). Further, the frequency of homozygous GG genotype was significantly increased among patients than controls (15.5% vs 5.0%, p=0.001, OR=3.49 (95% CI=1.7-7.13)). The patients with younger age at onset of disease (<14 years) had a significantly high frequency of G positive genotypes (A/G or G/G) than those with an older age at onset of disease (≥14 years) (66% vs 47.1%, p=0.007, OR=2.18 (95%CI=1.27-3.76). Further analysis involving the HLA data revealed that the CTLA4 +49G allele is not in linkage disequilibrium with the reported susceptible HLA-DR3 allele, however the susceptibility conferred by +49G allele as well as its effect on the disease onset was observed to be dependent on the presence of HLA-DR3 allele. These results suggest that CTLA4 +49G allele in the presence of HLA-DR3 allele not only confers susceptibility to T1D and but is a strong marker for acceleration of disease development